Science

Apr 24, 2025, 10:12

Myeloma Paper of the Day, April 24th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: IVIg supplementation in recipients of BCMA-directed TCEs for myeloma may be associated with improved outcomes, including favorable infection-free and overall survival; extramedullary and high-risk disease confer poor outcomes.”

“Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma”

Authors: Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi Shah, Carolina Schinke et al.

More posts featuring Robert Orlowski.

Aniko Szabo Anita D'Souza Anna Clennon cancer Carolina Schinke Heloise Cheruvalath Intravenous Immunoglobulin IVIG Mansi Shah Meera Mohan multiple myeloma Myeloma Paper of the Day Nishi Shah OncoDaily Oncology Rajshekhar Chakraborty Robert Orlowski Vineel Bhatlapenumarthi

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that